# Medicus Pharma Ltd.: overview MDCX · Nasdaq · CIK 1997296 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mdcx.md) · [Financials](/companies/mdcx/financials.md) · [Filings](/companies/mdcx/filings.md) · [Insiders](/companies/mdcx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.24)](/filings/0001062993-25-016838.md) | not reported | [(0.42)](/filings/0001062993-26-002629.md) | [(0.43)](/filings/0001062993-26-004230.md) | [(1.12)](/filings/0001062993-25-016838.md) | not reported | [(0.31)](/filings/0001062993-26-002629.md) | [(0.21)](/filings/0001062993-26-004230.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.53)](/filings/0001062993-25-006485.md) | [(1.16)](/filings/0001062993-26-001606.md) | [(2.74)](/filings/0001062993-26-001606.md) | | Free cash flow | $ | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mdcx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $39.4k | 60,600 | | Unchanged | | [Anson Funds Management LP](/funds/1491072.md) | 2026-06-30 | $18.9k | 42,400 | | Unchanged | | [Connective Capital Management, LLC](/funds/1543568.md) | 2026-06-30 | $3.9k | 6,000 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.4k | 2,203 | | Added +738 | ## Recent filings [All 341 filings](/companies/mdcx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:16 ET | [DEF 14A](/filings/0001062993-26-005627.md) | Proxy statement, period 2026-12-02 | 0001062993-26-005627 | | 2026-10-23 | 17:15 ET | [8-K](/filings/0001062993-26-005528.md) | 3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits | 0001062993-26-005528 | | 2026-10-16 | 16:55 ET | [8-K](/filings/0001062993-26-005382.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001062993-26-005382 | | 2026-10-07 | 16:05 ET | [8-K](/filings/0001062993-26-005226.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001062993-26-005226 | | 2026-09-14 | 16:39 ET | [SCHEDULE 13D](/filings/0000950142-26-002546.md) | Ownership report, active investor | 0000950142-26-002546 | | 2026-09-14 | 08:05 ET | [8-K](/filings/0001062993-26-004906.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001062993-26-004906 | | 2026-09-11 | 08:00 ET | [8-K](/filings/0001062993-26-004898.md) | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001062993-26-004898 | | 2026-09-03 | 08:00 ET | [8-K](/filings/0001062993-26-004806.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001062993-26-004806 | | 2026-08-12 | 17:19 ET | [10-Q](/filings/0001062993-26-004230.md) | Quarterly report, period 2026-06-30 | 0001062993-26-004230 | | 2026-06-04 | 16:30 ET | [8-K](/filings/0001062993-26-003060.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001062993-26-003060 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001062993-26-001606.md), filed Mar 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1997296 - Tickers: MDCX, MDCXW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A6 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:24 ET. No prices; not investment advice.